GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » 3-Year Book Growth Rate

Starpharma Holdings (Starpharma Holdings) 3-Year Book Growth Rate : 0.40% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings 3-Year Book Growth Rate?

Starpharma Holdings's Book Value per Share for the quarter that ended in Dec. 2023 was $0.56.

During the past 12 months, Starpharma Holdings's average Book Value per Share Growth Rate was -16.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was 0.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was -5.40% per year. During the past 10 years, the average Book Value per Share Growth Rate was -3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Starpharma Holdings was 13.70% per year. The lowest was -31.60% per year. And the median was 0.05% per year.


Competitive Comparison of Starpharma Holdings's 3-Year Book Growth Rate

For the Biotechnology subindustry, Starpharma Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's 3-Year Book Growth Rate falls into.



Starpharma Holdings 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.


Starpharma Holdings  (OTCPK:SPHRY) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.


Starpharma Holdings 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (Starpharma Holdings) Headlines

From GuruFocus

Starpharma to present at OTCQX Virtual Investor Conference

By PRNewswire PRNewswire 04-11-2018

Starpharma creates slow release soluble DEP remdesivir nanoparticle

By Business Wire Business Wire 09-01-2020

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma Presentation Now Available for On-Demand Viewing

By PRNewswire PRNewswire 04-17-2018

Starpharma signs new DEP� agreement with MSD

By PRNewswire PRNewswire 08-10-2022

Starpharma signs DEP� ADC Research Agreement with MSD

By PRNewswire PRNewswire 02-12-2021